Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
Memorial Sloan Kettering Cancer Center
University of Florida
Xencor, Inc.
Incyte Corporation
Calithera Biosciences, Inc
Augusta University
Shionogi Inc.
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Stanford University
Masonic Cancer Center, University of Minnesota
Novartis
Stanford University
Valerio Therapeutics
Valerio Therapeutics
University of Chicago